ClinicalTrials.gg
RecruitingNCT07328191Q-TRANSUpdated Feb 12, 2026

Quality of Life-Guided Transfusion in Refractory MDS or AML

An interventional study of Red blood cell transfusions based on EQ-5D-5L questionnaire in MDS, AML, Adult and Anemia, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Leukemia, Myeloid, Acute with a site in France — 64 open to participants now, 96 under way, 21 of them phase 3. Leukemia, Myeloid, Acute · France.

Planned enrollment
196th of 289
52 · median 100
Started
2026
with 11 others
No phase
29 of 342
9 open now
Primary completion
2027-02
later than 33 of 95 live
Registered
336th of 342
by date

Among the 342 studies in Leukemia, Myeloid, Acute with a site in France, this one is the 196th largest by planned enrollment of the 289 interventional ones that give a count, is one of 12 that started in 2026, is one of 29 with no phase, reaches primary completion later than 33 of the 95 other live ones, and was the 336th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

64 of the 342 studies in Leukemia, Myeloid, Acute with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Leukemia, Myeloid, Acute with a site in France, or all of them as a file.
02

Study summary

Patients with refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) in exclusive palliative care frequently receive red blood cell transfusions based on hemoglobin thresholds, despite limited evidence of clinical benefit in this setting.

This prospective randomized study compares a standard hemoglobin-based transfusion strategy to a quality-of-life-guided strategy using the EQ-5D-5L questionnaire, with the aim of reducing transfusion burden while maintaining patient safety and quality of life.

Read the detailed description

This is a prospective, single-center, randomized interventional study conducted in patients with transfusion-dependent refractory MDS or AML receiving exclusive palliative care. Palliative Care

Patients are randomized to either a standard transfusion strategy based on hemoglobin thresholds or a quality-of-life-guided strategy in which red blood cell transfusions are triggered by a clinically significant deterioration in EQ-5D-5L score.

The study aims to evaluate whether a quality-of-life-guided transfusion strategy can safely reduce the number of red blood cell transfusions without negatively impacting patient-reported outcomes.

03

Conditions studied

  • MDS
  • AML, Adult
  • Anemia

Keywords

  • palliative care
  • Chronic Transfusion-Dependent Anemia
  • Transfusion-dependent anemia
  • MDS
  • AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older.
  • Diagnosis of MDS or AML, receiving palliative care only.
  • Anaemia with ≤ 8 g/dl at inclusion (or ≤ 9 g/dl if associated with cardiovascular disease).
  • Transfusion dependency, defined as requiring more than 2 GR transfusions every 8 weeks.
  • No vitamin B9, vitamin B12 or iron deficiency.
  • Ability to understand and sign the form.
  • Ability to comply with the schedule of visits and other protocol requirements.

Non inclusion Criteria:

  • Previous malignant disease other than MDS or AML (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast).
  • Active uncontrolled infection ( or C, ).
  • Use of G-CSF.
  • Confirmed neurocognitive disorders (based on prior diagnosis or clinical assessment by the investigator) impairing comprehension, consent or the ability to reliably complete the EQ-5D-5L questionnaire.
  • Active uncontrolled heart disease.
  • Active haemolytic anaemia.
  • Recent major surgery.
  • Life-threatening complications of MDS/AML.
  • Presence of another serious or unstable disease which, in the investigators' opinion, would make participation in the study inappropriate or risky for the patient's safety.
  • Vulnerable individuals.

Exclusion criteria

Exclusion Criteria:

  • Immediate severe complications related to MDS/AML, such as uncontrolled bleeding, pneumonia with hypoxia or shock, or severe disseminated intravascular coagulopathy.
  • Withdrawal of the patient's voluntary .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • No intervention
    Hemoglobin-Based Transfusion Strategy

    Red blood cell transfusions are performed according to standard hemoglobin thresholds (Hb \<7 g/dL, or \<8 g/dL in patients with cardiovascular comorbidities). Standard of care arm

  • Experimental
    Quality of Life-Guided Transfusion Strategy

    Red blood cell transfusions are performed when a clinically significant deterioration (≥1 level decrease in at least one EQ-5D-5L domain compared to baseline) is observed

    Other: Red blood cell transfusions based on EQ-5D-5L questionnaire

Interventions

  • OtherRed blood cell transfusions based on EQ-5D-5L questionnaire

    Red blood cell transfusions are administered based on patient-reported quality-of-life assessments using the EQ-5D-5L questionnaire, collected weekly. A transfusion is performed when a deterioration of at least one level in any EQ-5D-5L dimension is observed.

06

What researchers measure

Primary outcomes

  1. Number of Red Blood Cell Transfusions

    Total number of red blood cell units transfused during the 2-month follow-up period.

    Time frame: 2 months

Secondary outcomes

  1. Quality of Life (EQ-5D-5L)

    Change in quality-of-life scores

    Time frame: from baseline to 1 month and 2 months.

  2. Overall Survival

    Survival status

    Time frame: from inclusion to 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 12 months is below that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Jan 9, 2026
StartActual
Feb 9, 2026
Primary completionEst.
Feb 9, 2027
CompletionEst.
Feb 9, 2028
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07328191
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Feb 9, 2026
Primary completion
Feb 9, 2027 (estimated)
Completion
Feb 9, 2028 (estimated)
Last update
Feb 12, 2026

Study contacts

Thomas Cluzeau, Professor
Contact
cluzeau.t@chu-nice.fr
0492039025
Lydia Cherfaoui
Contact
cherfaoui.l@chu-nice.fr
0492039025
Thomas Cluzeau
principal investigator · Centre Hospitalier Universitaire de Nice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion